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Objective: Arterial stiffness may be a mechanism to
explain the association between uric acid and
cardiovascular disease. We aimed to analyse associations
between serum uric acid and regional and local arterial
stiffness, and assess potential differences related to sex
and glucose metabolism status.
Methods: A cross-sectional study was performed in
614 adults [52.6% men; mean age 58.78.5 years;
23.2% type 2 diabetes mellitus (by design)] from The
Maastricht Study. Arterial stiffness was assessed by
carotid–femoral pulse wave velocity (cfPWV), distensibility,
and compliance coefficient of the carotid and femoral
artery, and carotid artery Young’s elastic modulus.
Results: Higher uric acid (per SD of 74 mmol/l) was
associated with greater stiffness indicated by a significantly
higher cfPWV [b¼0.216 (95% confidence interval 0.061,
0.372); P¼ 0.006] and lower carotid distensibility
coefficient [b¼0.633 (95% confidence interval 1.099,
0.166); P¼0.008] after adjustment for sex, age, and
glucose metabolism status. Associations lost significance
after adjusting for mean arterial pressure, BMI, waist,
smoking status, heart rate, total : high-density lipoprotein
cholesterol ratio, triglycerides, estimated glomerular
filtration rate, use of lipid-lowering, antihypertensive, and
diabetes medication, and use of secondary uricosurics. No
associations were found between uric acid and carotid
compliance coefficient, carotid Young’s elastic modulus,
or stiffness of the femoral artery. A significant interaction
(P<0.10) with glucose metabolism status was found for
cfPWV. However, none of the stratified associations were
significant. There was no interaction with sex.
Conclusion: Uric acid was not significantly associated with
stiffness of the aorta, or the carotid or femoral artery
among adults aged 40–75 years without and with type 2
diabetes mellitus.
Keywords: compliance coefficient, distensibility
coefficient, pulse wave velocity, uric acid, Young’s elastic
modulus
Abbreviations: DD, distension; baPWV, brachial–ankle
pulse wave velocity; cfPWV, carotid–femoral pulse wave
velocity; cIMT, carotid intima–media thickness; D, arterial
diameter; HR, heart rate; MAP, mean arterial pressure; PP,
pulse pressure; YEM, Young’s elastic modulus
INTRODUCTION
T
he prevalence of hyperuricaemia in the general
population has been estimated at 10–20% [1–4].
There is accumulating evidence that hyperuricaemia
is associated with cardiovascular disease (CVD) and its risk
factors [5]. The exact mechanisms underlying this associ-
ation, however, are not completely understood. Arterial
stiffness could be a mechanism that links uric acid to CVD.
Arterial stiffness is the loss of elastic properties of the
arterial wall and can contribute to CVD through the devel-
opment of systolic hypertension, left ventricular hypertro-
phy, and impaired coronary perfusion [6]. Stiffness is
affected by endothelial cell function and vascular smooth
muscle cell tone [7]. Both underlying processes have been
reported to be modified by uric acid [8–10]. Arterial stiffness
can be measured at different arterial segments and sites, and
by use of different techniques which include regional
carotid–femoral pulse wave velocity (cfPWV), brachial–
ankle PWV (baPWV), and local carotid and femoral stiff-
ness. Several studies have assessed the association between
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uric acid and regional arterial stiffness, with conflicting
results [11–21]. However, in most of these studies
[12,14,16–20], arterial stiffness was determined via the
assessment of baPWV. cfPWV is a more established index
of arterial stiffness and is considered the ‘gold standard’ [6].
cfPWV involves a mixture of elastic and muscular arterial
parts of the arterial tree, and is independently associated
with CVD [22,23]. Studies examining the association
between uric acid and cfPWV, however, have also shown
inconsistent results [11,15,21,24–28], possibly due to
incomplete adjustment for confounding factors such as
glucose metabolism status [11,24], renal function [11], mean
arterial pressure [26], or antihypertensive medication [25],
and a large variation in study populations.
Studies that investigated the relation between uric acid
and local arterial stiffness indices are scarce [29,30]. How-
ever, assessing local carotid stiffness indices may be of
importance [6]. The carotid artery is a frequent site of
atheroma formation [6], and combined with greater carotid
stiffness, the risk of ischemic stroke may increase [31]. This
could be explained by the association between increased
pulse pressure (PP) and plaque instability [32]. In addition,
stiffening of peripheral arteries, such as the femoral artery,
may also be important in the development of CVD, because
stiffness of these arteries may boost the premature return of
reflected pulse waves [33].
Previous longitudinal studies have reported a stronger
relation between uric acid and CVD or mortality in women
than in men [34,35]. In addition, research suggests a differ-
ence in the association between uric acid and CVD accord-
ing to glucose metabolism status [36], possibly due to a
biological interaction between uric acid, glucose, and insu-
lin concentrations [37,38]. In view of these considerations,
we investigated whether uric acid is associated with cfPWV,
local carotid and/or femoral stiffness. In addition, inter-
actions between uric acid, sex, and glucose metabolism
status were assessed.
METHODS
Study population and design
In this study, we used data from The Maastricht Study, an
observational prospective population-based cohort study.
The rationale and methodology have been described pre-
viously [39]. In brief, the study focuses on the aetiology,
pathophysiology, complications, and comorbidities of type
2 diabetes mellitus (T2DM) and is characterized by an
extensive phenotyping approach. Eligible for participation
were all individuals aged between 40 and 75 years and
living in the southern part of the Netherlands. Participants
were recruited through mass media campaigns, and from
the municipal registries and the regional Diabetes Patient
Registry via mailings. Recruitment was stratified according
to known T2DM status for reasons of efficiency. The
present report includes cross-sectional data from the first
866 participants, who completed the baseline survey
between November 2010 and March 2012. The examin-
ations of each participant were performed within a time
window of 3 months. The study has been approved by the
institutional medical ethical committee (NL31329.068.10)
and the Netherlands Health Council under the Dutch ‘Law
for Population Studies’ (Permit 131088–105234-PG). All
participants gave written informed consent.
For the present study, we excluded patients without data
on uric acid (N¼ 13), cfPWV (N¼ 43), local carotid stiffness
(N¼ 54), local femoral stiffness (N¼ 86), smoking status
(N¼ 17), BMI (N¼ 1), waist (N¼ 3), cholesterol concen-
trations (N¼ 8), and/or estimated glomerular filtration rate
(eGFR) (N¼ 9). We also excluded individuals with type 1
diabetes (N¼ 4) or a history of CVD (N¼ 152). A history of
CVD was defined as self-reported myocardial infarction;
cerebrovascular infarction or haemorrhage; and/or percu-
taneous artery angioplasty or vascular surgery of the cor-
onary, abdominal, peripheral, or carotid arteries according
to the Rose questionnaire [40]. Furthermore, individuals
taking any uric acid-lowering medication (i.e. allopurinol
or benzbromaron; N¼ 21) were excluded. The total study
population thus consisted of 614 participants.
Arterial stiffness measurements
All measurements were done by trained vascular tech-
nicians, unaware of the participants’ clinical or diabetes
status, in a dark, quiet, temperature-controlled room
(21–238C). Participants were asked to refrain from smoking
and drinking coffee, tea, or alcoholic beverages 3 h prior
to the study. Participants were allowed to have a light
meal (breakfast and/or lunch). All measurements were
performed in the supine position after 10min of rest. Talk-
ing or sleeping was not allowed during the examination.
During the vascular measurements (approximately 45min),
brachial systolic, diastolic, and mean arterial pressure
(MAP) were determined every 5min with an oscillometric
device (Accutorr Plus, Datascope Inc., Montvale, New
Jersey, USA). The mean MAP and heart rate (HR) of these
measurements were used in the statistical analysis. A three-
lead electrocardiogram was recorded continuously during
the measurements to facilitate automatic signal processing.
Carotid–femoral pulse wave velocity
Carotid–femoral PWV was determined according to recent
guidelines [41], with the use of applanation tonometry
(SphygmoCor, Atcor Medical, Sydney, Australia). Pressure
waveforms were determined at the right common carotid
and right common femoral arteries. The difference in the
time of pulse arrival from the R-wave of the electrocardio-
gram between the two sites (transit time) was determined
with the intersecting tangents algorithm. The pulse wave
travel distance was calculated as 80% of the direct straight
distance (measured with an infantometer) between the
two arterial sites. The median of three consecutive cfPWV
(defined as travelled distance/transit time) recordings was
used in the analyses.
Local arterial stiffness
Measurements were done at the left common carotid
(10 mm proximal to the carotid bulb) and the right common
femoral (10–20mm proximal to the flow divider) arteries,
with the use of an ultrasound scanner equipped with a
7.5-MHz linear probe (MyLab 70, Esaote Europe B.V.,
Maastricht, the Netherlands). This set-up enables the
measurement of diameter, distension, and intima-media
Uric acid and arterial stiffness
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thickness (IMT) as described previously [42,43]. Briefly,
during the ultrasound measurements, a B-mode image
on the basis of 19 M-lines was depicted on screen. An
online echo-tracking algorithm showed real-time anterior
and posterior wall displacements. The M-mode recordings
were composed of 19 simultaneous recordings at a frame
rate of 498 Hz. The distance between the M-line recording
positions was 0.96 mm; thus, a total segment of 18.24 mm of
each artery was covered by the scan plane. For offline
processing, the radiofrequency signal was fed into a dedi-
cated computer-based acquisition system (ART.LAB, Esaote
Europe B.V. Maastricht, the Netherlands) with a sampling
frequency of 50MHz. Data processing was performed in
MatLab (version 7.5; Mathworks, Natick, Massachusetts,
USA). The distension waveforms were obtained from the
radiofrequency data with the use of a wall track algorithm
[42]. Carotid IMT was defined as the distance of the
posterior wall from the leading edge interface between
lumen and intima to the leading edge interface between
media and adventitia [43]. The median diameter, distension
and IMT of the three measurements were used in the
analyses.
Data analysis was done by quantifying the local arterial
elastic properties through the calculation of the following
indices [44]:
1. Distensibility coefficient¼ (2DDDþDD2)/(PPD2)
(10–3/kPa)
2. Young’s elastic modulus (YEM) (carotid artery
only)¼D/(IMTdistensibility coefficient) (103 kPa)
3. Compliance coefficient¼p (2DDDþDD2)/4PP
(mm2/kPa)
where D is the arterial diameter; DD is the distension;
IMT the intima–media thickness; and PP the pulse pressure
(i.e. brachial and carotid PP for calculating femoral and
carotid stiffness indices, respectively). Brachial PP was
calculated as SBP minus DBP. Carotid PP was calculated
according to the calibration method described by Kelly and
Fitchett [45], with the use of carotid tonometry wave forms
as adapted by van Bortel et al. [46]. This method assumes a
constant difference between MAP and diastolic pressure
along the arterial tree. PP can then be calculated at a carotid
artery (PPcar) from the uncalibrated carotid pressure wave-
form using the formula: PPcar¼PPcaruncalibrated (Kbrach/
Kcaruncalibrated), in which K is defined as (MAPdiastolic
pressure). For the carotid artery, diastolic pressure and MAP
are calculated as the minimum and the area under the
tonometry waveform divided by time, respectively.
Distensibility coefficient represents arterial stiffness;
YEM, the stiffness of the arterial wall material at operating
pressure; and compliance coefficient, the arterial buffering
capacity. Note that higher values of cfPWV or carotid YEM,
and lower values of distensibility coefficient or compliance
coefficient denote greater arterial stiffness, that is, lower
arterial elasticity.
Reproducibility was assessed by two observers in
12 individuals (6 men, 60.8 6.8 years; 6 individuals with
T2DM) who were examined on two occasions spaced
1 week apart. The intra-observer and inter-observer
intra-class correlation coefficients were 0.87 and 0.69 for
cfPWV; 0.85 and 0.73 for carotid distensibility coefficient;
0.95 and 0.72 for carotid compliance coefficient; 0.72 and
0.71 for carotid YEM; 0.49 and 0.32 for femoral distensibility
coefficient; and 0.41 and 0.67 for femoral compliance
coefficient.
Other covariates
After an overnight fast, venous blood samples were
collected at The Maastricht Study research centre. Plasma
glucose was measured with a standard enzymatic hexo-
kinase reference method, and serum total cholesterol,
high-density lipoprotein (HDL) cholesterol, triglycerides,
creatinine, and uric acid concentrations were measured
with standard (enzymatic and/or colourimetric) methods
by an automatic analyser (Beckman Synchron LX20; Beck-
man Coulter Inc., Brea, USA) at Maastricht University
Medical Centre (the Netherlands). Measurement of creati-
nine was based on the Jaffé method traceable to isotope
dilution mass spectrometry (Synchron LX20; Beckman
Coulter Inc.). Height (in centimetres) was measured with
individuals standing upright against a stadiometer. Body
weight was measured on an analogue scale (Seca 761; Seca,
Hamburg, Germany). BMI was calculated as body weight
(kg) divided by height squared (m2). Waist circumference
was measured in duplicate midway between the lower rib
margin and the iliac crest at the end of expiration, to the
nearest 0.5 cm, with a flexible plastic tape measure (Seca).
Participants were requested to bring all the medication
they used at the time of measurement or a list from their
pharmacists to the research centre. During a medication
interview generic name, dose and frequency, and
additional over-the-counter (OTC) medication use were
registered by trained staff. All participants received an
extensive web-based questionnaire in which smoking
behaviour (never, former, current) and years of diabetes
duration was self-reported. SBP and DBP was determined
three times on the right arm after a 10-min resting period,
using a blood pressure monitor (Omron 705 IT; Omron,
Japan). The average of the three measurements was calcu-
lated. Hypertension was defined as office SBP above 140
mmHg, or DBP above 90 mmHg, and/or current antihy-
pertensive medication use. Renal function as estimated
by GFR (in ml/min per 1.73 m2) was calculated with the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula [47]. To determine glucose metabolism,
all participants (except those who used insulin) underwent
a standardized 2-h-75-g oral glucose tolerance test (OGTT)
after an overnight fast. For safety reasons, participants with
a fasting glucose level above 11.0 mmol/l (N¼ 13) were
excluded from the OGTT. Glucose metabolism status was
classified according to the WHO 2006 criteria [48] as: normal
glucose metabolism (NGM) in case of fasting plasma glu-
cose concentrations below 6.1 mmol/l and 2-h post-glucose
concentrations below 7.8 mmol/l; impaired glucose toler-
ance (IGT) in case of fasting plasma glucose below
7.0 mmol/l and 2-h post-glucose at least 7.8 mmol/l and
less than 11.1mmol/l; impaired fasting glucose (IFG) in case
of fasting plasma glucose 6.1–6.9 mmol/l and (if measured)
2-h post-glucose below 7.8 mmol/l; and T2DM in case
of fasting plasma glucose at least 7.0 mmol/l and/or 2-h
Wijnands et al.
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post-glucose at least 11.1 mmol/l. For this study, we defined
having either IFG or IGT as impaired glucose metabolism
(IGM).
Statistical analysis
All analyses were performed using IBM SPSS version 19.0
(SPSS, Chicago, Illinois, USA). General characteristics of the
study population were compared across tertiles of uric acid
concentrations using analysis of variance (ANOVA) for
continuous variables and chi-square test for categorical
variables. Multivariable linear regression analyses were
used to determine the association between uric acid [per
þ1 standard deviation (SD), SD¼ 74 mmol/l] and arterial
stiffness indices (cfPWV, carotid distensibility coefficient,
carotid compliance coefficient, carotid YEM, femoral dis-
tensibility coefficient, and femoral compliance coefficient).
The associations were first adjusted for age, sex, and
glucose metabolism status (model 1). Additionally, the
associations were adjusted for BMI, waist, smoking status,
HR (for analyses with cfPWV only), total : HDL cholesterol
ratio, triglycerides, eGFR, use of lipid-lowering and diabe-
tes medication, renin–angiotensin–aldosterone system
inhibitors, and other antihypertensive medication (includ-
ing beta-blockers) that have no known uricosuric proper-
ties, and antihypertensive and lipid-lowering medication
that may have a uricosuric effect, that is, secondary urico-
surics [including losartan (N¼ 14) [49,50], amlodipine
(N¼ 18) [51], atorvastatin (N¼ 39) [52], and rosuvastatin
(N¼ 36)] [52] (model 2). None of the individuals used
fenofibrate [53].
Arteries become stiffer when they are distended [54] and
therefore stiffness is highly dependent on blood pressure.
Elastin fibres bear the load at physiologic pressures, while
collagen fibres remain folded [55]. However, with increas-
ing pressures, stiffer collagen fibres are recruited causing an
increase in stiffness. In order to disentangle the effects of
blood pressure from differences in stiffness properties of
the arterial wall per se, we additionally adjusted for MAP in
models 1 and 2. Interactions between uric acid and sex or
glucose metabolism status were tested in model 2 þ MAP
using F change. Additionally, over-adjustment by eGFR as a
potential intermediate variable in the association between
uric acid and arterial stiffness indices was evaluated by
excluding eGFR from model 2 þ MAP [56,57].
A P value less than 0.05 was considered statistically
significant, except for the interaction analyses, where
P value less than 0.10 was used.
RESULTS
Table 1 shows the general characteristics of the study
population according to uric acid tertiles. Of the total
population of 614 individuals, 323 (52.6%) were men.
The average age was 58.7 years. A large percentage of
individuals had T2DM (23.2%) or hypertension (50.5%).
Individuals in the third uric acid tertile were significantly
older, more frequently male, and more often had T2DM and
hypertension. Individuals excluded because of missing data
had slightly higher uric acid concentrations, had a higher
BMI, and more often had T2DM, hypertension, and a
kidney function below 60ml/min per 1.73 m2 (Supple-
mentary Table 1, http://links.lww.com/HJH/A482).
Uric acid and regional arterial stiffness
Linear regression analysis, adjusted for age, sex, and glu-
cose metabolism status, showed that a 1 SD (74 mmol/l)
higher serum uric acid concentration was associated with a
higher cfPWV [b¼ 0.216; 95% confidence interval (CI)
0.061, 0.372; P¼ 0.006] (Table 2, model 1). After adjustment
for MAP, the association became non-significant (b¼ 0.108;
95% CI —0.031, 0.247; P¼ 0.127). Additional adjustment for
BMI, waist, smoking status, HR, total : HDL cholesterol ratio,
triglycerides, eGFR, use of lipid-lowering, diabetes, and
antihypertensive medication, and secondary uricosurics,
did not materially change the results (b¼ 0.110; 95% CI
0.055, 0.275; P¼ 0.190) (Table 2, model 2þMAP). Results
of model 2 with or without adjustment for MAP were
similar (b¼ 0.134; 95% CI 0.048, 0.317; P¼ 0.149)
(Table 2, model 2). No interaction between uric acid and
sex (P for interaction¼ 0.589) was identified in the associ-
ation between uric acid and cfPWV. Glucose metabolism
status modified the association (P for interaction¼ 0.096).
However, after full adjustment (model 2þMAP), uric acid
was not significantly associated with cfPWV in any of the
subgroups of individuals with normal glucose metabolism
(N¼ 369) (b¼0.127; 95% CI 0.329, 0.076; P¼ 0.219),
IGM (N¼ 102) (b¼ 0.206; 95% CI0.188, 0.601; P¼ 0.301),
or with T2DM (N¼ 143) (b¼ 0.338; 95% CI 0.075, 0.752;
P¼ 0.108).
Uric acid and local arterial stiffness
After adjustment for age, sex, and glucose metabolism
status, higher uric acid was associated with greater stiffness
indicated by a significantly lower carotid distensibility co-
efficient (b¼0.663; 95% CI 1.099, 0.166; P¼ 0.008)
(Table 3, model 1). Uric acid was not associated with carotid
compliance coefficient, carotid YEM, femoral distensibility
coefficient, or femoral compliance coefficient (Table 3,
model 1). The significant association with carotid distensi-
bility coefficient was lost after adjustment for MAP
(b¼0.268; 95% CI 0.672, 0.136; P¼ 0.193) (Table 3,
model 1þMAP). Additional adjustment for the confound-
ing factors in model 2 did not materially change the result
(b¼0.196; 95% CI 0.679, 0.288; P¼ 0.427) (Table 3,
model 2þMAP). Results of model 2 with or without adjust-
ment for MAP were similar (b¼0.287; 95% CI 0.845,
0.271; P¼ 0.313) (Table 3, model 2).
No significant interactions between uric acid, sex, and
glucose metabolism status were identified in the associ-
ations between uric acid and any of the local stiffness
indices (data not shown – all P values for interaction
>0.110).
Additional analyses
After excluding eGFR from the list of confounders in
model 2þMAP, the association between uric acid and
cfPWV became stronger (b¼ 0.171; 95% CI 0.012, 0.329;
P¼ 0.035). Excluding eGFR from the analyses did not
change the results of the associations between uric acid
and the local stiffness indices (data not shown).
Uric acid and arterial stiffness
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DISCUSSION
Accumulating evidence suggests that uric acid is associated
with CVD [5]. Arterial stiffness, as one of the precursors of
CVD, could therefore be among the underlying mechan-
isms. However, we found no evidence that uric acid was
significantly associated with cfPWV or local carotid and
femoral arterial stiffness indices in this population-based
cohort study (including 23.2% with T2DM) of adults aged
40–75 years.
Non-significant associations between uric acid and
cfPWV were also found in previous cross-sectional studies
among normotensive (N¼ 656) [25], untreated hypertensive
(N¼ 647 and N¼ 292) [25,27], or hypertensive (N¼ 366)
individuals [24]. Similarly, no association was found by Lim
et al. [26] in a healthy population free of CVD, diabetes,
renal disease, hypertension, or dyslipidaemia (N¼ 1276). In
contrast, Liang et al. [15] did find a positive association
between uric acid and cfPWV in a comparable, but larger,
population (N¼ 3772). Independent associations were also
found in never-treated hypertensive individuals (N¼ 1225)
[21] and among workers (N¼ 940) [11]. The heterogeneity
in terms of sample size, population characteristics, and the
adjustments made for confounding factors such as glucose












Uric acid (mmol/l) 34674 26729 33920 43147 <0.001
Age (years) 58.78.5 57.48.1 58.68.7 60.18.5 0.007
Male sex (%) 52.6 24.0 58.3 74.3 <0.001
BMI (kg/m2) 26.84.3 25.03.7 26.73.8 28.84.5 <0.001
Waist circumference (cm) 95.512.8 88.911.9 94.911.5 102.511.4 <0.001
Smoking (%) 0.321
Never 33.1 35.2 31.5 33.7
Past 51.5 46.9 51.9 55.4
Current 15.5 17.9 16.7 11.9
Total cholesterol-to-HDL ratio 4.21.3 3.71.1 4.31.3 4.71.4 <0.001
Triglycerides (mmol/l) 1.18 (0.83; 1.74) 0.92 (0.67; 1.34) 1.26 (0.84; 1.69) 1.48 (1.05; 2.24) <0.001
Use of lipid-lowering medicationb (%) 15.3 8.2 18.5 18.8 0.003
eGFR (ml/min per 1.73 m2) 85.914.2 89.212.2 87.313.5 81.415.4 <0.001
eGFR <60 ml/min per 1.73 m2 (%) 4.7 1.0 3.2 9.9 <0.001
Glucose metabolism status (%) <0.001
Normal glucose metabolism 60.1 76.0 60.2 44.6
Impaired glucose metabolism 16.6 8.7 17.1 23.8
Type 2 diabetes 23.2 15.3 22.7 31.7
Diabetes treatment among individuals with
type 2 diabetesc (%)
0.002
No medication 23.1 26.7 24.5 20.3
Oral medicationd 60.8 46.7 61.2 67.2
Insulin with or without oral medication 16.1 26.6 14.3 12.5
Diabetes durationc (years) 7.0 (3.0; 11.0) 7.0 (3.3; 11.8) 6.0 (3.0; 11.0) 7.0 (2.0; 10.0) 0.767
Hypertension (%) 50.5 31.1 53.7 65.8 <0.001
Use of antihypertensive medication among
individuals with hypertensionb,e (%)
Use of RAAS inhibitors 39.7 37.7 31.9 47.4 0.042
Use of other antihypertensive medication 38.7 26.2 34.5 48.1 0.007
Use of secondary uricosurics (%) 15.8 13.8 16.2 17.3 0.611
Mean arterial pressure (mmHg) 97.410.1 94.510.7 98.49.9 99.29.2 <0.001
Brachial pulse pressure (mmHg) 51.19.8 48.69.4 51.79.9 52.99.5 <0.001
Carotid pulse pressuref (mmHg) 49.913.6 46.912.7 50.414.0 52.213.7 <0.001
Heart rate (b.p.m.) 68.210.4 68.510.0 67.410.3 68.810.8 0.390
Carotid–femoral pulse wave velocity (m/s) 8.72.0 8.21.7 8.81.9 9.22.3 <0.001
Carotid arteryg
Distensibility coefficient (10–3/kPa) 15.36.3 16.26.9 15.36.1 14.45.8 0.015
Compliance coefficient (mm2/kPa) 0.690.30 0.680.30 0.700.29 0.680.30 0.687
Young’s elastic modulus (103 kPa) 0.720.39 0.680.44 0.700.36 0.760.35 0.093
Femoral arteryh
Distensibility coefficient (10–3/kPa) 14.48.2 14.97.4 14.18.4 14.28.7 0.625
Compliance coefficient (mm2/kPa) 1.060.63 1.010.52 1.070.67 1.090.69 0.393
ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; RAAS, renin–angiotensin–aldosterone system. Data are reported as mean SD,
median (inter-quartile range), or percentage as appropriate.
aOn the basis of ANOVA for continuous variables and chi-square tests for categorical variables.
bNot including medication that have known uricosuric properties.
cIndividuals with type 2 diabetes: overall (N¼143); lowest tertile (N¼30); middle tertile (N¼ 49); highest tertile (N¼64).
dIncluding use of GLP-1 agonist (N¼2).
eIndividuals with hypertension: overall (N¼310); lowest tertile (N¼61); middle tertile (N¼116); highest tertile (N¼133).
fCarotid pulse pressure (N¼613).
gCarotid distensibility and compliance coefficient (N¼601), Young’s elastic modulus (N¼ 600).
hFemoral distensibility and compliance coefficient (N¼574).
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metabolism status or kidney function, between these
studies, is large. We found no clear reason to explain the
discrepancies in results.
Femoral and carotid arteries differ with regard to struc-
ture and function [58]. The muscular femoral artery has
more vascular smooth muscle cells and a higher collagen-
to-elastin ratio, and stiffening of this artery is less influenced
by age and blood pressure than stiffening of the carotid
artery [58]. In the present study, we found no difference in
the associations between uric acid and femoral stiffness or
carotid stiffness. In line with our study, Cipolli et al. [29] did
not identify an association between uric acid and carotid
YEM or carotid compliance coefficient in 338 individuals
with hypertension. In addition, an association between uric
acid and carotid distensibility coefficient was not found
among young adults [30]. Our study is the first to evaluate
the association between uric acid and the femoral artery
and to compare the potential effect of uric acid on both
carotid and femoral vessels.
In our models, we distinguished between effects of
blood pressure on arterial stiffness and differences in stiff-
ness properties of the arterial wall per se. After adding MAP
to model 1 the b-coefficients decreased substantially. This
suggests that the associations between uric acid, cfPWV,
and carotid distensibility coefficient in model 1 were
attributable to MAP. However, after adjusting model 1 for
the confounding factors in model 2, additional adjustment
for MAP did not influence our results. MAP is correlated
with the confounding factors in model 2, such as kidney
function and BMI. Since the independent effects of these
factors cannot be disentangled, we cannot draw firm con-
clusions on the role of MAP in the association between uric
acid and arterial stiffness.
A previous study found that a 1 SD increase in age
(SD¼ 8.5 years), MAP (SD¼ 9.6 mmHg), or triglyceride
concentrations (SD¼ 64.1 mg/dl) was significantly associ-
ated with an increase in cfPWV of 1.04, 0.59, and 0.24 m/s,
respectively [59]. In our study, a 1 SD (74 mmol/l) increase in
uric acid concentration was non-significantly (P¼ 0.190)
associated with a 0.110 m/s higher cfPWV. Therefore, the
magnitude of the association found in our study implies a
very small, if any, contribution of uric acid to the develop-
ment of aortic stiffness.
Excluding kidney function from the list of confounders
in the additional analyses resulted in a stronger association
between uric acid and cfPWV. This may be explained by the
association between kidney function and arterial stiffness
[56], and/or the association between kidney function and
uric acid [57]. We cannot conclude whether kidney function
acts as a confounder and/or as a mediator.
In our study, we did not find significant sex-related
interactions in the associations between uric acid and
any of the arterial stiffness indices. This is in line with other
studies that investigated the association between uric acid
and cfPWV in the general population [15] or in individuals
with newly diagnosed hypertension [21]. In contrast, Chen
et al. [11] identified a stronger relation between uric acid
and arterial stiffness among men. An increase of 100 mmol/l
serum uric acid was significantly associated with an
increase of 0.15 m/s in cfPWV among men, whereas there
was no association among women. The authors suggested
that the null finding among women may be attributable to
the small percentage of women with hyperuricaemia [11].
Although sex differences in the impact of elevated serum
uric acid concentrations on CVD have often been observed,
explanations for these differences are still lacking.
It has been suggested that uric acid may have a different
effect on cardiovascular mortality according to glucose
TABLE 2. The association between uric acid and regional
stiffness
cfPWV (m/s)b
ba 95% CI P value
Model 1 0.216 0.061, 0.372 0.006
Model 1þMAP 0.108 0.031, 0.247 0.127
Model 2 0.134 0.048, 0.317 0.149
Model 2þMAP 0.110 0.055, 0.275 0.190
Model 1: adjusted for sex, age, and glucose metabolism status. Model 2: model 1 þ
adjusted for heart rate, BMI, waist, smoking, total : HDL cholesterol, triglycerides, eGFR,
use of lipid-lowering, diabetes, and antihypertensive medication, and use of secondary
uricosurics. cfPWV, carotid–femoral pulse wave velocity; CI, confidence interval; eGFR,
estimated glomerular filtration rate; HDL, high-density lipoprotein; MAP, mean arterial
pressure.
aUric acid expressed per standard deviation (74 mmol/l).
bN¼614.
TABLE 3. The association between uric acid and local stiffness of the carotid and femoral artery
DC (10–3/kPa) CC (mm2/kPa) YEM (103 kPa)b
ba 95% CI P value ba 95% CI P value ba 95% CI P value
Carotid arteryc
Model 1 0.633 1.099, —0.166 0.008 0.020 0.044, 0.003 0.091 0.020 0.012, 0.052 0.220
Model 1 þ MAP 0.268 0.672, 0.136 0.193 0.007 0.029, 0.015 0.522 0.002 0.028, 0.032 0.902
Model 2 0.287 0.845, 0.271 0.313 0.016 0.044, 0.013 0.277 0.006 0.033, 0.045 0.752
Model 2 þ MAP 0.196 0.679, 0.288 0.427 0.012 0.039, 0.014 0.361 0.002 0.035, 0.038 0.930
Femoral arteryd
Model 1 0.522 1.283, 0.239 0.179 0.027 0.084, 0.029 0.343
Model 1 þ MAP 0.197 0.937, 0.542 0.600 0.006 0.062, 0.050 0.832
Model 2 0.019 0.903, 0.940 0.968 0.003 0.065, 0.072 0.920
Model 2 þ MAP 0.139 0.755, 1.032 0.761 0.011 0.055, 0.078 0.739
Model 1: adjusted for sex, age, glucose metabolism status. Model 2: model 1 þ adjusted for BMI, waist, smoking, total : HDL cholesterol, triglycerides, eGFR, use of lipid-lowering,
diabetes, and antihypertensive medication and use of secondary uricosurics. CC, compliance coefficient; CI, confidence interval; DC, distensibility coefficient; eGFR, estimated glomerular
filtration rate; HDL, high-density lipoprotein; MAP, mean arterial pressure; YEM, Young’s elastic modules.
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metabolism status [36], because of the possible biological
interaction between uric acid, glucose, and insulin concen-
trations [37,38]. The Maastricht Study cohort was designed
to find potential contrasts between individuals with and
without T2DM. In the present study, we found a significant
interaction between uric acid and glucose metabolism
status in the association with cfPWV. The stratified results
may suggest that the detrimental effect of uric acid is more
apparent among individuals with IGM or T2DM as com-
pared to those with normal glucose metabolism. However,
we want to stress that none of the stratified associations was
significant and the b-coefficients of the associations were
relatively small. Furthermore, the subgroups according to
glucose metabolism status differed in size. We therefore
emphasize the need for replication of our findings on the
glucose metabolism-related differences.
A limitation of this study is the exclusion of a proportion
(5–10%) of individuals from the analyses because of
missing values on one of the arterial stiffness indices.
However, we assumed these missing values to be missing
at random because most values were missing due to logistic
factors such as the unavailability of a vascular ultrasound
technologist. A further limitation is that the cross-sectional
design does not allow conclusions on cause-and-effect
relations.
The study was strengthened by the comprehensive
evaluation of arterial stiffness, using both regional as well
as local arterial stiffness indices. Moreover, vascular echog-
raphy data were collected by trained vascular ultrasound
technologists and benefited from the high repeatability of
the aortic and carotid stiffness measurements. Additionally,
due to the extensive phenotyping, we were able to adjust
for a series of potential confounders.
In conclusion, we found no significant association
between uric acid and aortic, carotid, or femoral stiffness
among 614 adults aged 40–75 years without and with
T2DM.
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The study adds fuel to the heated debate on the role of uric
acid in arterial stiffness. Contradictory data have been
published so far on the matter. The novelty of the study
is the simultaneous assessment both of regional and local
arterial stiffness. Limitations of the study include the small
size of the cohort, which is limited to ages 40–75, where
patients with type 2 diabetes mellitus are over-represented.
Reviewer 2
The aim of the study was to analyze associations between
circulating uric acid and indices of arterial stiffness in a
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general population. The authors’ conclusion is that higher
uric acid is associated with greater arterial stiffness, as
indicated by significantly higher carotid-femoral pulse
wave velocity; however this association is no more signifi-
cant after adjustment for confounding factors.
The issue explored and the results obtained are interest-
ing, suggesting that the observed association between uric
acid and cardiovascular disease is not a direct one, but it is
mediated by other risk factors. However, different results
were obtained in at least another study.
Wijnands et al.
1650 www.jhypertension.com Volume 33  Number 8  August 2015
